Full Press Release Details
Sinovac Schedules 2013
Annual Meeting of Shareholders
BEIJING, July 19, 2013 -- Sinovac Biotech Ltd. (NASDAQ: SVA),
a leading provider of biopharmaceutical products in China, announced today that it will hold its 2013 Annual Meeting of Shareholders
on Wednesday, August 21, 2013 at 9:00 a.m. Beijing Time. The meeting will be held at No. 39 Shangdi Xi Road, Haidian District,
Beijing, PRC. All shareholders of record as of July 3, 2013 will be eligible to vote and are invited to attend.
The primary agenda of the meeting is to approve the re-election
of Weidong Yin, Yuk Lam Lo, Simon Anderson, Kenneth Lee and Meng Mei as the Company's directors until the next annual meeting
of shareholders and or until their successors are duly elected; approve the audited consolidated financial statements of the Company
for the financial year ended December 31, 2012 together with the Report of Independent Registered Public Accounting Firm thereon
and the notes thereto; approve the appointment of Ernst &Young Hua Ming LLP as the independent auditor of the Company
for the fiscal year ending December 31, 2013 and to authorize the directors of the Company to fix such independent auditor's
Sinovac's 2012 annual report and proxy statements, including
the Notice of the 2013 Annual General Meeting, are available on the Company's website: http://www.sinovac.com/?optionid=751.
Shareholders of the Company may receive a hard copy of 20-F
free of charge upon request. Such request can be made by sending an e-mail to ir@sinovac.com, along with complete contact details
and a mailing address.
Sinovac Biotech Ltd. is a China-based biopharmaceutical company
that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious
diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu) and mumps,
as well as animal rabies vaccine for canines. The Company recently concluded the phase III clinical trial for enterovirus 71 (against
hand, foot and mouth disease). In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza
vaccine, Panflu.1, and has manufactured it for the Chinese Central Government, pursuant to the government-stockpiling program. The
Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government-stockpiling program. Sinovac is developing
a number of new pipeline vaccines including vaccines for pneumococcal polysaccharides, pneumococcal conjugate, varicella and rubella.
Sinovac sells its vaccines mainly in China and exports selected vaccines to Mongolia, Nepal, and the Philippines. Sinovac has also
been granted a license to commercialize seasonal flu vaccine in Mexico.
Safe Harbor Statement
This announcement contains forward-looking statements. These
statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995.
These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar statements.
Among other things, the business outlook and quotations from management in this press release contain forward-looking statements.
Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements.
Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to
differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any
forward-looking statement, except as required under applicable law.
Helen Yang/Chris Lee
Sinovac Biotech Ltd.
Tel: +86-10-8279-9659/9696
Fax: +86-10-6296-6910
Email: ir@sinovac.com
Stephanie Carrington
Tel: +1-646-536-7017
Email: scarrington@theruthgroup.com
Tel: +1-646-536-7028
Email: aestrada@theruthgroup.com